title: Suppression of familial adenomatous polyposis by CP-31398, a TP53 modulator, in APCmin/+ mice.
abstract: p53 mutations occur in a large number of human malignancies. Mutant p53 is unable to affect downstream genes necessary for DNA repair, cell cycle regulation, and apoptosis. The styrylquinazoline CP-31398 can rescue destabilized mutant p53 expression and promote activity of wild-type p53. The present study examines chemopreventive effects of CP-31398 on intestinal adenoma development in an animal model of familial adenomatous polyposis. Effects were examined at both early and late stages of adenoma formation. Effects of CP-31398 on early-stage adenomas were determined by feeding 7-week-old female C57BL/6J-APC(min) (heterozygous) and wild-type C57BL/6J mice with American Institute of Nutrition-76A diets containing 0, 100, or 200 ppm of CP-31398 for 75 days. To examine activity toward late-stage adenomas, CP-31398 administration was delayed until 15 weeks of age and continued for 50 days. During early-stage intervention, dietary CP-31398 suppressed development of intestinal tumors by 36% (P < 0.001) and 75% (P < 0.0001), at low and high dose, respectively. During late-stage intervention, CP-31398 also significantly suppressed intestinal polyp formation, albeit to a lesser extent than observed with early intervention. Adenomas in treated mice showed increased apoptotic cell death and decreased proliferation in conjunction with increased expression of p53, p21(WAF1/CIP), cleaved caspase-3, and cleaved poly(ADP-ribose) polymerase. These observations show for the first time that the p53-modulating agent CP-31398 possesses significant chemopreventive activity in vivo against intestinal neoplastic lesions in genetically predisposed APC(min/+) mice. Chemopreventive activity of other agents that restore tumor suppressor functions of mutant p53 in tumor cells is currently under investigation.
authors.affiliation: Department of Medicine, Hem-Onc Section, University of Oklahoma Cancer Institute, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA. cv-rao@ouhsc.edu
authors.forename: Chinthalapally V
authors.initials: CV
authors.lastname: Rao
authors.forename: Malisetty V
authors.initials: MV
authors.lastname: Swamy
authors.forename: Jagan M R
authors.initials: JM
authors.lastname: Patlolla
authors.forename: Levy
authors.initials: L
authors.lastname: Kopelovich
mesh_terms: D011125:Adenomatous Polyposis Coli / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D053148:Caspase 3 / Q000378:metabolism; D048708:Cell Growth Processes / Q000187:drug effects; D050759:Cyclin-Dependent Kinase Inhibitor p21 / Q000235:genetics / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005260:Female; D017491:Genes, APC; D007414:Intestinal Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D011065:Poly(ADP-ribose) Polymerases / Q000378:metabolism; D011743:Pyrimidines / Q000494:pharmacology*; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000378:metabolism*
chemical_list: C493957:Cdkn1a protein, mouse; D050759:Cyclin-Dependent Kinase Inhibitor p21; D011743:Pyrimidines; D016159:Tumor Suppressor Protein p53; D011065:Poly(ADP-ribose) Polymerases; D053148:Caspase 3; C402665:CP 31398
references.citation: Oncogene. 2003 Jul 17;22(29):4478-87
references.pmid: 12881704
references.citation: Br J Haematol. 2004 Nov;127(3):285-91
references.pmid: 15491287
references.citation: Eur J Cancer. 1995 Jul-Aug;31A(7-8):1033-8
references.pmid: 7576987
references.citation: Nature. 2007 Feb 8;445(7128):661-5
references.pmid: 17251932
references.citation: Science. 2004 Feb 6;303(5659):844-8
references.pmid: 14704432
references.citation: Mol Cell. 2003 Mar;11(3):577-90
references.pmid: 12667443
references.citation: Nat Med. 2004 Aug;10(8):789-99
references.pmid: 15286780
references.citation: J Natl Cancer Inst. 1986 Dec;77(6):1241-6
references.pmid: 3467115
references.citation: Science. 1990 Jan 19;247(4940):322-4
references.pmid: 2296722
references.citation: J Biol Chem. 2004 Oct 29;279(44):45887-96
references.pmid: 15308639
references.citation: Oncogene. 1996 Dec 5;13(11):2477-82
references.pmid: 8957091
references.citation: Carcinogenesis. 2000 Apr;21(4):617-21
references.pmid: 10753194
references.citation: Nat Rev Cancer. 2001 Oct;1(1):68-76
references.pmid: 11900253
references.citation: Cancer Res. 1996 Feb 15;56(4):710-4
references.pmid: 8631000
references.citation: Cancer Res. 2006 Jul 15;66(14):7370-7
references.pmid: 16849589
references.citation: J Am Chem Soc. 2007 Mar 7;129(9):2456-7
references.pmid: 17284038
references.citation: Nat Med. 2002 Mar;8(3):282-8
references.pmid: 11875500
references.citation: Cancer Cell. 2003 Nov;4(5):371-81
references.pmid: 14667504
references.citation: J Clin Invest. 2007 Dec;117(12):3753-64
references.pmid: 18060030
references.citation: Nature. 1997 Apr 24;386(6627):761, 763
references.pmid: 9126728
references.citation: Oncogene. 2000 Mar 2;19(10):1245-56
references.pmid: 10713666
references.citation: Exp Cell Res. 2002 Jun 10;276(2):214-22
references.pmid: 12027451
references.citation: Curr Cancer Drug Targets. 2004 Feb;4(1):29-42
references.pmid: 14965265
references.citation: Cancer Biol Ther. 2002 Jan-Feb;1(1):47-55
references.pmid: 12174820
references.citation: Cancer Res. 2003 Sep 1;63(17):5239-42
references.pmid: 14500353
references.citation: Nat Med. 1996 Oct;2(10):1143-6
references.pmid: 8837616
references.citation: Cell. 2007 Mar 9;128(5):837-40
references.pmid: 17350571
references.citation: Mol Cell Biol. 2003 Mar;23(6):2171-81
references.pmid: 12612087
references.citation: Trends Biotechnol. 2004 Sep;22(9):431-4
references.pmid: 15331219
references.citation: Cell. 2003 Mar 21;112(6):779-91
references.pmid: 12654245
references.citation: Proc Natl Acad Sci U S A. 2006 Jul 18;103(29):11003-8
references.pmid: 16835297
references.citation: Proc Natl Acad Sci U S A. 1990 Oct;87(19):7555-9
references.pmid: 1699228
references.citation: Carcinogenesis. 2003 Feb;24(2):263-7
references.pmid: 12584176
references.citation: Cell. 2000 Nov 22;103(5):691-4
references.pmid: 11114324
references.citation: Cancer Res. 1994 Nov 15;54(22):5947-52
references.pmid: 7954427
references.citation: Science. 1999 Dec 24;286(5449):2507-10
references.pmid: 10617466
references.citation: Nature. 2007 Feb 8;445(7128):656-60
references.pmid: 17251933